Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 270

1.

Pseudomonas aeruginosa arylsulfatase: a purified enzyme for the mild hydrolysis of steroid sulfates.

Stevenson BJ, Waller CC, Ma P, Li K, Cawley AT, Ollis DL, McLeod MD.

Drug Test Anal. 2015 Mar 5. doi: 10.1002/dta.1782. [Epub ahead of print]

PMID:
25739756
2.

[The Wrong Suspected Diagnosis of a Glomus Jugulare Tumor.]

Jakob TF, Waller CF, Offergeld C.

Laryngorhinootologie. 2015 Mar 4. [Epub ahead of print] German. No abstract available.

PMID:
25739069
3.

Fragment library design: using cheminformatics and expert chemists to fill gaps in existing fragment libraries.

Kutchukian PS, So SS, Fischer C, Waller CL.

Methods Mol Biol. 2015;1289:43-53. doi: 10.1007/978-1-4939-2486-8_5.

PMID:
25709032
4.

OPTN/SRTR 2013 Annual Data Report: heart.

Colvin-Adams M, Smith JM, Heubner BM, Skeans MA, Edwards LB, Waller CD, Callahan ER, Snyder JJ, Israni AK, Kasiske BL.

Am J Transplant. 2015 Jan;15 Suppl 2:1-28. doi: 10.1111/ajt.13199.

PMID:
25626345
5.

An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.

Waller CF, Vynnychenko I, Bondarenko I, Shparyk Y, Hodge JP, Freeman A, Huber B, Lieberman R, Shelton MJ, Dave H.

Clin Lung Cancer. 2015 Mar;16(2):92-9. doi: 10.1016/j.cllc.2014.10.001. Epub 2014 Oct 15.

PMID:
25458558
6.

A simple method for the small scale synthesis and solid-phase extraction purification of steroid sulfates.

Waller CC, McLeod MD.

Steroids. 2014 Dec;92:74-80. doi: 10.1016/j.steroids.2014.09.006. Epub 2014 Oct 5.

PMID:
25286236
7.

[Gender-specific aspects of coronary heart disease].

Ladwig KH, Waller C.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Sep;57(9):1083-91. doi: 10.1007/s00103-014-2020-6. German.

PMID:
25112950
8.

Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.

Hörsch D, Schmid KW, Anlauf M, Darwiche K, Denecke T, Baum RP, Spitzweg C, Grohé C, Presselt N, Stremmel C, Heigener DF, Serke M, Kegel T, Pavel M, Waller CF, Deppermann KM, Arnold R, Huber RM, Weber MM, Hoffmann H.

Oncol Res Treat. 2014;37(5):266-76. doi: 10.1159/000362430. Epub 2014 Apr 14. Review.

PMID:
24853787
9.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

10.

Position paper on the importance of psychosocial factors in cardiology: Update 2013.

Ladwig KH, Lederbogen F, Albus C, Angermann C, Borggrefe M, Fischer D, Fritzsche K, Haass M, Jordan J, Jünger J, Kindermann I, Köllner V, Kuhn B, Scherer M, Seyfarth M, Völler H, Waller C, Herrmann-Lingen C.

Ger Med Sci. 2014 May 7;12:Doc09. doi: 10.3205/000194. eCollection 2014.

11.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
12.

Imatinib mesylate.

Waller CF.

Recent Results Cancer Res. 2014;201:1-25. doi: 10.1007/978-3-642-54490-3_1. Review.

PMID:
24756783
13.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jul;93(7):1167-76.

14.

Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera.

Ahlgrim C, Schumacher YO, Wrobel N, Waller CF, Pottgiesser T.

Ann Hematol. 2014 Jul;93(7):1159-65. doi: 10.1007/s00277-014-2020-5. Epub 2014 Feb 1.

PMID:
24488226
15.

OPTN/SRTR 2012 Annual Data Report: heart.

Colvin-Adams M, Smithy JM, Heubner BM, Skeans MA, Edwards LB, Waller C, Schnitzler MA, Snyder JJ, Israni AK, Kasiske BL.

Am J Transplant. 2014 Jan;14 Suppl 1:113-38. doi: 10.1111/ajt.12583.

16.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team.

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

PMID:
24331154
17.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A.

J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.

18.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jan;93(1):71-80. doi: 10.1007/s00277-013-1937-4. Epub 2013 Oct 27.

19.

Neural correlates of experimentally induced flow experiences.

Ulrich M, Keller J, Hoenig K, Waller C, Grön G.

Neuroimage. 2014 Feb 1;86:194-202. doi: 10.1016/j.neuroimage.2013.08.019. Epub 2013 Aug 17.

20.

COX-2 inhibitory activity of homoisoflavanones and xanthones from the bulbs of the Southern African Ledebouria socialis and Ledebouria ovatifolia (Hyacinthaceae: Hyacinthoideae).

Waller CP, Thumser AE, Langat MK, Crouch NR, Mulholland DA.

Phytochemistry. 2013 Nov;95:284-90. doi: 10.1016/j.phytochem.2013.06.024. Epub 2013 Jul 13.

PMID:
23859260
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk